Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)- Insider Own47.84% Shs Outstand21.38M Perf Week-7.56%
Market Cap81.03M Forward P/E- EPS next Y- Insider Trans0.76% Shs Float11.15M Perf Month6.76%
Income- PEG- EPS next Q-0.58 Inst Own52.16% Short Float / Ratio5.14% / 4.22 Perf Quarter-68.42%
Sales- P/S- EPS this Y- Inst Trans- Short Interest0.57M Perf Half Y-
Book/sh4.58 P/B0.83 EPS next Y- ROA- Target Price42.67 Perf Year-
Cash/sh4.76 P/C0.80 EPS next 5Y- ROE- 52W Range2.13 - 18.33 Perf YTD-76.24%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.32% Beta-
Dividend %- Quick Ratio20.36 Sales past 5Y0.00% Gross Margin- 52W Low77.93% ATR0.64
Employees10 Current Ratio20.36 Sales Q/Q- Oper. Margin- RSI (14)46.62 Volatility18.92% 19.30%
OptionableNo Debt/Eq0.00 EPS Q/Q-14.48% Profit Margin- Rel Volume1.07 Prev Close3.82
ShortableYes LT Debt/Eq0.00 EarningsNov 13 BMO Payout- Avg Volume135.77K Price3.79
Recom1.00 SMA2013.99% SMA50-27.73% SMA200-60.00% Volume144,989 Change-0.79%
Date Action Analyst Rating Change Price Target Change
Aug-08-23Initiated TD Cowen Outperform
Aug-08-23Initiated Piper Sandler Overweight $67
Aug-08-23Initiated JMP Securities Mkt Outperform $30
Aug-08-23Initiated Goldman Buy $33
Nov-28-23 08:00AM
Nov-22-23 08:00AM
Nov-13-23 08:00AM
Nov-10-23 08:30AM
Oct-24-23 11:00AM
04:05PM Loading…
Oct-18-23 04:05PM
Sep-27-23 04:05PM
Aug-29-23 10:21AM
Aug-21-23 04:02PM
Aug-15-23 04:04PM
Aug-08-23 10:02AM
Jul-20-23 04:05PM
Jul-13-23 09:10PM
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Happel DavidPresident & CEONov 16Buy2.355901,386590Nov 20 09:59 PM
Kemble GeorgeExecutive ChairmanSep 07Option Exercise0.795,6304,4485,630Sep 08 04:15 PM
SEIDENBERG BETH CDirectorJul 18Buy16.0046,875750,00046,875Jul 20 04:20 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerJul 18Buy16.0030,000480,0003,850,275Jul 20 06:56 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerJul 18Sale16.0066210,5923,820,275Jul 20 06:56 PM